Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In tumors, a subset of CD8 T cells expressing the transcription factor TCF-1 drives the response to immune checkpoint blockade. We examined the mechanisms that maintain these cells in an autochthonous model of lung adenocarcinoma. Longitudinal sampling and single-cell sequencing of tumor-antigen specific TCF-1 CD8 T cells revealed that while intratumoral TCF-1 CD8 T cells acquired dysfunctional features and decreased in number as tumors progressed, TCF-1 CD8 T cell frequency in the tumor draining LN (dLN) remained stable. Two discrete intratumoral TCF-1 CD8 T cell subsets developed over time-a proliferative SlamF6 subset and a non-cycling SlamF6 subset. Blocking dLN egress decreased the frequency of intratumoral SlamF6 TCF-1 CD8 T cells. Conventional type I dendritic cell (cDC1) in dLN decreased in number with tumor progression, and Flt3L+anti-CD40 treatment recovered SlamF6 T cell frequencies and decreased tumor burden. Thus, cDC1s in tumor dLN maintain a reservoir of TCF-1 CD8 T cells and their decrease contributes to failed anti-tumor immunity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604155 | PMC |
| http://dx.doi.org/10.1016/j.immuni.2021.08.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Succinate preserves CD8 T cell fitness to augment antitumor immunity.
Immunity
August 2025
National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu 215123, China; Key Laboratory of Synthetic Biology Regulatory Element, Institute of Systems Medicine, Chinese Academy of Med
Succinate, a tricarboxylic acid cycle intermediate, accumulates in tumors with succinate dehydrogenase (SDH) mutations. Although succinate is recognized for modulating CD8 T cell cytotoxicity, its impact on T cell differentiation remains poorly understood. Here, we reveal that succinate accumulation in tumors lacking the SDH subunit B (SDHB) enhanced tumor-reactive CD8 T cell-mediated immune responses.
View Article and Find Full Text PDFTGF-β and IL-12 conversely orchestrate the formation of CD103 CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine.
iScience
August 2025
INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
The accumulation of CD103 CD8 tumor-resident memory T (T) cells is predictive of response to cancer immunotherapy. Here, we show that a therapeutic peptide vaccine controls tumor growth in wild-type mice, but not in CD103-knockout mice. CD8 tumor-infiltrating T lymphocytes include two major T subpopulations expressing either CD49a or CD103 integrin, with a subset co-expressing CD103 and Tcf-1.
View Article and Find Full Text PDFIntegrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma.
J Exp Clin Cancer Res
July 2025
Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Background: We developed an integrated multi-omics analysis in metastatic melanoma (MM) cohorts to associate DNA methylation profiles with tumor progression, survival, response to adjuvant immunotherapy, structure of the tumor immune microenvironment and transcriptional programs of immunity and melanoma differentiation.
Methods: Lesions (n = 191) from a fully annotated, retrospective cohort of 165 AJCC 8th Stage III and IV melanoma patients (EPICA cohort) were characterized by reduced representation bisulfite sequencing, RNA sequencing, whole exome sequencing, quantitative immunohistochemistry and multiplex immunofluorescence analysis. The TCGA melanoma datasets were used for validation.
Tim-3 Promotes Early Differentiation of Tbet Effector T Cells During Acute Viral Infection.
bioRxiv
July 2025
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
The transmembrane protein Tim-3 has received significant attention in recent years as a possible immunotherapy target. This is due to its robust expression on dysfunctional, exhausted, T cells found in the settings of cancer and chronic infection and biochemical evidence suggesting an inhibitory function of Tim-3. However, numerous clinical trials of putative Tim-3 blocking antibodies have yielded modest benefits, at best, in clinical trials for various cancers.
View Article and Find Full Text PDFSelective expansion of TCF7-expressing tumor-reactive T cell subpopulations during ovarian tumor-infiltrating T cell production ex vivo.
Sci China Life Sci
July 2025
Shanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Tumor-infiltrating lymphocyte (TIL) therapy was recently approved for melanoma patients; however, the dynamic changes in T cell subpopulations during TIL production remain poorly understood. Here, we analyzed epithelial ovarian cancer samples at various stages of ex vivo TIL culture using paired single-cell RNA and TCR sequencing. We also assessed the expansion potential and tumor reactivity of the identified TIL subpopulations.
View Article and Find Full Text PDF